Zorubicin

Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas[1][2][3][4][5].

[1]Alberts DS, Van Daalen Wetters T. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Br J Cancer. 1976 Jul;34(1):64-8.|[2]Barlogie B, et al. Kinetic response to cultured human lymphoid cells to rubidazone. J Natl Cancer Inst. 1978 Feb;60(2):279-82.|[3]Herman EH, Young RS. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog. Cancer Treat Rep.|[4]Sartiano GP, et al. Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. J Antibiot (Tokyo). 1979 Oct;32(10):1038-45. |[5]Akerman KJ, et al. Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc. 2014 Apr 16;136(15):5670-82.